

Drugs and Devices Division

Drug Submission Status

Report for September 2019

Complete Streamlined Multiple-Source

Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Laboratoire Riva Inc.	Riva-Labetalol	Trandate	labetalol HCl	100 mg	F.C. tablet	02489406
Laboratoire Riva Inc.	Riva-Labetalol	Trandate	labetalol HCl	200 mg	F.C. tablet	02489414
Jamp Pharma Corporation	Jamp-Emtricitabine / Tenofovir Disoproxil Fumarate	Truvada	emtricitabine / tenofovir disoproxil fumarate	200mg/300 mg	Tablet	02487012